HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

GSK2110183

an Akt inhibitor with antineoplastic activity; structure in first source

Networked: 4 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Polyamines: 3918
    - Diamines: 518
      - GSK2110183: 4
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - GSK2110183: 4

Experts

1.	Chen, Xi: 1 article (04/2021)
2.	Cheng, Shuyuan: 1 article (04/2021)
3.	Dai, Xiaoyang: 1 article (04/2021)
4.	Ding, Ling: 1 article (04/2021)
5.	Guo, Hongjie: 1 article (04/2021)
6.	Guo, Qingqu: 1 article (04/2021)
7.	Wang, Jian: 1 article (04/2021)
8.	Wang, Tingting: 1 article (04/2021)
9.	Xu, Xiaqing: 1 article (04/2021)
10.	Zhang, Wenxin: 1 article (04/2021)

Related Diseases

1.	Stomach Neoplasms (Stomach Cancer) 04/05/2021 - "Obviously, Ceritinib improved the sensitivity of Capivasertib (AZD5363, AKTs) and Afuresertib (GSK2110183, AKTis) in gastric cancer cells, as illustrated by a significant reduction in the GC cell proliferation and enhanced apoptosis. "
2.	Ovarian Neoplasms (Ovarian Cancer) 08/01/2020 - "Here, we tested and compared a panel of 16 PI3K/AKT/mTOR inhibitors (XL765, Miltefosine, Rapamycin, CCI-779, RAD001, FK506, XL147, GSK2110183, IPI-145, GSK2141795, BYL719, GSK458, CAL-101, XL765 analogue SAR245409, Triciribine, and GDC0941) that have entered clinical trials for antitumor activity against ovarian cancer, as well as the front line drug, paclitaxel. "
3.	Neoplasms (Cancer) 01/01/2020 - "There have been several promising drug candidates that have been studied, including but not limited to ipatasertib (RG7440), 1; afuresertib (GSK2110183), 2; uprosertib (GSK2141795), 3; capivasertib (AZD5363), 4; which reportedly bind to the ATP active site and inhibit Akt activity, thus exerting cytotoxic and antiproliferative activities against human cancer cells. "
4.	Breast Neoplasms (Breast Cancer) 01/01/2021 - "To better understand how these drugs exert their therapeutic effects at the molecular level, we combined chemoproteomic target affinity profiling using kinobeads and phosphoproteomics to analyze the five clinical AKT inhibitors AZD5363 (Capivasertib), GSK2110183 (Afuresertib), GSK690693, Ipatasertib, and MK-2206 in BT-474 breast cancer cells. "

Related Drugs and Biologics

1.	capivasertib
2.	afuresertib
3.	ceritinib
4.	GSK2141795
5.	Sirolimus (Rapamycin)
6.	Paclitaxel (Taxol)
7.	Tacrolimus (Prograf)
8.	MTOR Inhibitors
9.	Everolimus
10.	Alpelisib